Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 9/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788630 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL11886413 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL17190976 | 0.89 | L3MBTL1 (0.59) | SMN1; SMN2MAPTALDH1A1L3MBTL1HPGD | |
| SCHEMBL17190983 | 0.89 | ALDH1A1 (0.56) | MAPTALDH1A1L3MBTL1HPGDHTT | |
| SCHEMBL13167840 | 0.89 | ALDH1A1 (0.56) | MAPTALDH1A1L3MBTL1HPGDHTT | |
| SCHEMBL8950340 | 0.83 | L3MBTL1 (0.47) | SMN1; SMN2MAPTALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL22420907 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPTALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL15449619 | 0.79 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL13130682 | 0.79 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL14692225 | 0.79 | CD44 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388197-B2 | Heterocyclic amide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-07-12 | — | — | US | disclosed |
| US-20150361096-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-12-17 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| WO-2014115072-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-07-31 | — | — | WO | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8563732-B2 | Oxyimino compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20130252957-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8367836-B2 | Pyridinone antagonists of alpha-4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110009407-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100240703-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252957-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ITGA4, ITGB4, ITGB5 | SMN1; SMN2 2633/4885MAPT 248/4885ALDH1A1 829/4885 |
| US-20110009407-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ITGA4, ITGB4, ITGB5 | SMN1; SMN2 2633/4885MAPT 248/4885ALDH1A1 829/4885 |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | SMN1; SMN2 1858/4885MAPT 679/4885ALDH1A1 2796/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | SMN1; SMN2 1157/4885MAPT 26/4885ALDH1A1 2082/4885 |
| US-20100240703-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | CACNA1A, CACNA1S, OPRM1 | SMN1; SMN2 476/4885MAPT 3109/4885ALDH1A1 886/4885 |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | PAK2, PAK3, PAK4 | SMN1; SMN2 2578/4885MAPT 699/4885ALDH1A1 2121/4885 |
| US-20150361096-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX3 | SMN1; SMN2 4453/4885MAPT 3932/4885ALDH1A1 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.